Canlyniadau Chwilio - Raoul Tibes

Mireinio'r Canlyniadau
  1. 1
    <i>Ex vivo</i>activity of BCL-2 family inhibitors ABT-199 and ABT-737 combined with 5-azacytidine in myeloid malignancies

    <i>Ex vivo</i>activity of BCL-2 family inhibitors ABT-199 and ABT-737 combined with 5-azacytidine in myeloid malignancies gan James M. Bogenberger, Devora Delman, Nanna Hansen, Riccardo Valdez, Veena Fauble, Ruben A. Mesa, Raoul Tibes

    Cyhoeddwyd 2014
    Cael y testun llawn
    Carta
    Ychwanegu at ffefrynnau
    Wedi'i Gadw mewn:
  2. 2
    Prospective feasibility analysis of reduced-intensity conditioning (RIC) regimens for hematopoietic stem cell transplantation (HSCT) in elderly patients with acute myeloid leukemia (AML) and high-risk myelodysplastic syndrome (MDS)

    Prospective feasibility analysis of reduced-intensity conditioning (RIC) regimens for hematopoietic stem cell transplantation (HSCT) in elderly patients with acute myeloid leukemia... gan Elihu H. Estey, Marcos de Lima, Raoul Tibes, Sherry Pierce, Hagop Kantarjian, Richard E. Champlin, Sergio Giralt

    Cyhoeddwyd 2006
    Cael y testun llawn
    Artigo
    Ychwanegu at ffefrynnau
    Wedi'i Gadw mewn:
  3. 3
    Dynamic reprogramming of DNA methylation in SETD2-deregulated renal cell carcinoma

    Dynamic reprogramming of DNA methylation in SETD2-deregulated renal cell carcinoma gan Rochelle L. Tiedemann, Ryan A. Hlady, Paul D. Hanavan, Douglas F. Lake, Raoul Tibes, Jeong‐Heon Lee, Jeong‐Hyeon Choi, Thai H. Ho, Keith D. Robertson

    Cyhoeddwyd 2015
    Cael y testun llawn Cael y testun llawn
    Artigo
    Ychwanegu at ffefrynnau
    Wedi'i Gadw mewn:
  4. 4
    Phase I ficlatuzumab monotherapy or with erlotinib for refractory advanced solid tumours and multiple myeloma

    Phase I ficlatuzumab monotherapy or with erlotinib for refractory advanced solid tumours and multiple myeloma gan Amita Patnaik, Glen J. Weiss, K. Papadopoulos, Craig C. Hofmeister, Raoul Tibes, Anthony W. Tolcher, Robin Isaacs, J. Jac, May Han, Francis Payumo, Monette Cotreau, Rajesh Ramanathan

    Cyhoeddwyd 2014
    Cael y testun llawn Cael y testun llawn
    Artigo
    Ychwanegu at ffefrynnau
    Wedi'i Gadw mewn:
  5. 5
    The Hedgehog pathway as targetable vulnerability with 5-azacytidine in myelodysplastic syndrome and acute myeloid leukemia

    The Hedgehog pathway as targetable vulnerability with 5-azacytidine in myelodysplastic syndrome and acute myeloid leukemia gan Raoul Tibes, Aref Al‐Kali, Gavin R. Oliver, Devora H. Delman, Nanna Hansen, Keerthi Bhagavatula, Mohan Jayaram, Fariborz Rakhshan, Thomas Wood, James M. Foran, Ruben A. Mesa, James M. Bogenberger

    Cyhoeddwyd 2015
    Cael y testun llawn Cael y testun llawn
    Artigo
    Ychwanegu at ffefrynnau
    Wedi'i Gadw mewn:
  6. 6
    Targeting Mitochondrial Structure Sensitizes Acute Myeloid Leukemia to Venetoclax Treatment

    Targeting Mitochondrial Structure Sensitizes Acute Myeloid Leukemia to Venetoclax Treatment gan Xufeng Chen, Christina Glytsou, Hua Zhou, Sonali Narang, Denis E. Reyna, Andrea López, Theodore Sakellaropoulos, Yixiao Gong, Andreas Kloetgen, Yoon Sing Yap, Eric Wang, Evripidis Gavathiotis, Aristotelis Tsirigos, Raoul Tibes, Iannis Aifantis

    Cyhoeddwyd 2019
    Cael y testun llawn Cael y testun llawn
    Artigo
    Ychwanegu at ffefrynnau
    Wedi'i Gadw mewn:
  7. 7
    A phase I trial of the human double minute 2 inhibitor (MK-8242) in patients with refractory/recurrent acute myelogenous leukemia (AML)

    A phase I trial of the human double minute 2 inhibitor (MK-8242) in patients with refractory/recurrent acute myelogenous leukemia (AML) gan Farhad Ravandi, Ivana Gojo, Mrinal M. Patnaik, Mark D. Minden, Hagop M. Kantarjian, Amy O. Johnson‐Levonas, Craig Fancourt, Raymond W. Lam, Mary Jones, Clayton D. Knox, Shelonitda Rose, Payal Patel, Raoul Tibes

    Cyhoeddwyd 2016
    Cael y testun llawn
    Artigo
    Ychwanegu at ffefrynnau
    Wedi'i Gadw mewn:
  8. 8
    RNAi screening of the kinome with cytarabine in leukemias

    RNAi screening of the kinome with cytarabine in leukemias gan Raoul Tibes, James M. Bogenberger, Leena Chaudhuri, R. Tanner Hagelstrom, Donald Chow, Megan Buechel, Irma M. Gonzales, Tim Demuth, James L. Slack, Ruben A. Mesa, Esteban Braggio, Hongwei Yin, Shilpi Arora, David O. Azorsa

    Cyhoeddwyd 2012
    Cael y testun llawn Cael y testun llawn
    Artigo
    Ychwanegu at ffefrynnau
    Wedi'i Gadw mewn:
  9. 9
    Synergistic Targeting of AML Stem/Progenitor Cells With IAP Antagonist Birinapant and Demethylating Agents

    Synergistic Targeting of AML Stem/Progenitor Cells With IAP Antagonist Birinapant and Demethylating Agents gan Bing Z. Carter, Po Yee Mak, Duncan H. Mak, Yuexi Shi, Yihua Qiu, James M. Bogenberger, Hong Mu, Raoul Tibes, Hui Yao, Kevin R. Coombes, Rodrigo Jácamo, Teresa McQueen, Steven M. Kornblau, Michael Andreeff

    Cyhoeddwyd 2014
    Cael y testun llawn Cael y testun llawn
    Artigo
    Ychwanegu at ffefrynnau
    Wedi'i Gadw mewn:
  10. 10
    CHK1 and WEE1 inhibition combine synergistically to enhance therapeutic efficacy in acute myeloid leukemia ex vivo

    CHK1 and WEE1 inhibition combine synergistically to enhance therapeutic efficacy in acute myeloid leukemia ex vivo gan Leena Chaudhuri, Nicole D. Vincelette, Brian D. Koh, Ryan M. Naylor, Karen S. Flatten, Kevin L. Peterson, Andrew McNally, Ivana Gojo, Judith E. Karp, Ruben A. Mesa, Lisa Sproat, James M. Bogenberger, Scott H. Kaufmann, Raoul Tibes

    Cyhoeddwyd 2013
    Cael y testun llawn Cael y testun llawn
    Artigo
    Ychwanegu at ffefrynnau
    Wedi'i Gadw mewn:
  11. 11
    Panel sequencing for clinically oriented variant screening and copy number detection in 142 untreated multiple myeloma patients

    Panel sequencing for clinically oriented variant screening and copy number detection in 142 untreated multiple myeloma patients gan K. Martin Kortuem, Esteban Braggio, Laura A. Bruins, Santiago Barrio, Chenlai Shi, Ya-Jie Zhu, Raoul Tibes, David S. Viswanatha, Patrick G. Votruba, Gregory Ahmann, Rafaël Fonseca, Patrick Jedlowski, Ilana Schlam, Shaji Kumar, P. Leif Bergsagel, A. Keith Stewart

    Cyhoeddwyd 2016
    Cael y testun llawn Cael y testun llawn
    Artigo
    Ychwanegu at ffefrynnau
    Wedi'i Gadw mewn:
  12. 12
    Association of Therapy for Autoimmune Disease With Myelodysplastic Syndromes and Acute Myeloid Leukemia

    Association of Therapy for Autoimmune Disease With Myelodysplastic Syndromes and Acute Myeloid Leukemia gan Natalie Ertz-Archambault, Heidi E. Kosiorek, Gretchen Taylor, Katalin Kelemen, Amylou C. Dueck, Janna C. Castro, Robert Marino, Susanne M. Gauthier, Laura Finn, Lisa Z. Sproat, Jeanne Palmer, Ruben A. Mesa, Aref Al‐Kali, James M. Foran, Raoul Tibes

    Cyhoeddwyd 2017
    Cael y testun llawn
    Artigo
    Ychwanegu at ffefrynnau
    Wedi'i Gadw mewn:
  13. 13
    Phase 1 Study of the Safety, Tolerability, and Pharmacokinetics of TH-302, a Hypoxia-Activated Prodrug, in Patients with Advanced Solid Malignancies

    Phase 1 Study of the Safety, Tolerability, and Pharmacokinetics of TH-302, a Hypoxia-Activated Prodrug, in Patients with Advanced Solid Malignancies gan Glen J. Weiss, Jeffrey R. Infante, E. Gabriela Chiorean, Mitesh J. Borad, Johanna C. Bendell, Julian R. Molina, Raoul Tibes, Ramesh K. Ramanathan, Karen Lewandowski, Suzanne F. Jones, Mario E. Lacouture, Virginia K. Langmuir, Hank Lee, Stew Kroll, Howard A. Burris

    Cyhoeddwyd 2011
    Cael y testun llawn Cael y testun llawn
    Artigo
    Ychwanegu at ffefrynnau
    Wedi'i Gadw mewn:
  14. 14
    Phase I Study of the Hedgehog Pathway Inhibitor IPI-926 in Adult Patients with Solid Tumors

    Phase I Study of the Hedgehog Pathway Inhibitor IPI-926 in Adult Patients with Solid Tumors gan Antonio Jimeno, Glen J. Weiss, Wilson H. Miller, Scott Gettinger, Bernhard J. Eigl, Anne Lynn S. Chang, Joi Dunbar, Shannon Devens, L. Kerrie, Georgios Skliris, Jeff Kutok, Karl D. Lewis, Raoul Tibes, William H. Sharfman, Robert W. Ross, Charles M. Rudin

    Cyhoeddwyd 2013
    Cael y testun llawn Cael y testun llawn
    Artigo
    Ychwanegu at ffefrynnau
    Wedi'i Gadw mewn:
  15. 15
    Phase I Trial of Hedgehog Pathway Inhibitor Vismodegib (GDC-0449) in Patients with Refractory, Locally Advanced or Metastatic Solid Tumors

    Phase I Trial of Hedgehog Pathway Inhibitor Vismodegib (GDC-0449) in Patients with Refractory, Locally Advanced or Metastatic Solid Tumors gan Patricia LoRusso, Charles M. Rudin, Josina C. Reddy, Raoul Tibes, Glen J. Weiss, Mitesh J. Borad, Christine L. Hann, Julie R. Brahmer, Ilsung Chang, Walter C. Darbonne, Richard Graham, Kenn L. Zerivitz, Jennifer A. Low, Daniel D. Von Hoff

    Cyhoeddwyd 2011
    Cael y testun llawn
    Artigo
    Ychwanegu at ffefrynnau
    Wedi'i Gadw mewn:
  16. 16
    Randomized phase II trial of cytosine arabinoside with and without the CHK1 inhibitor MK-8776 in relapsed and refractory acute myeloid leukemia

    Randomized phase II trial of cytosine arabinoside with and without the CHK1 inhibitor MK-8776 in relapsed and refractory acute myeloid leukemia gan Jonathan Webster, Raoul Tibes, Larry Morris, Amanda L. Blackford, Mark R. Litzow, Mrinal M. Patnaik, Gary L. Rosner, Ivana Gojo, Robert J. Kinders, Lihua Wang, L. Austin Doyle, Catherine J. Huntoon, Larry M. Karnitz, Scott H. Kaufmann, Judith E. Karp, B. Douglas Smith

    Cyhoeddwyd 2017
    Cael y testun llawn
    Artigo
    Ychwanegu at ffefrynnau
    Wedi'i Gadw mewn:
  17. 17
    Combined venetoclax and alvocidib in acute myeloid leukemia

    Combined venetoclax and alvocidib in acute myeloid leukemia gan James M. Bogenberger, Clifford J. Whatcott, Nanna Hansen, Devora Delman, Chang-Xin Shi, Wontak Kim, Hillary Haws, Katherine K. Soh, Ye Sol Lee, Peter Peterson, Adam Siddiqui-Jain, Steven Weitman, Keith Stewart, David J. Bearss, Ruben A. Mesa, Steven L. Warner, Raoul Tibes

    Cyhoeddwyd 2017
    Cael y testun llawn Cael y testun llawn
    Artigo
    Ychwanegu at ffefrynnau
    Wedi'i Gadw mewn:
  18. 18
    Mitophagy Promotes Resistance to BH3 Mimetics in Acute Myeloid Leukemia

    Mitophagy Promotes Resistance to BH3 Mimetics in Acute Myeloid Leukemia gan Christina Glytsou, Xufeng Chen, Emmanouil Zacharioudakis, Wafa Al-Santli, Hua Zhou, Bettina Nadorp, Soobeom Lee, Audrey Lasry, Zhengxi Sun, Dimitrios Papaioannou, Michael Cammer, Kun Wang, Tomasz Żal, Malgorzata Anna Zal, Bing Z. Carter, Jo Ishizawa, Raoul Tibes, Aristotelis Tsirigos, Michael Andreeff, Evripidis Gavathiotis, Iannis Aifantis

    Cyhoeddwyd 2023
    Cael y testun llawn
    Artigo
    Ychwanegu at ffefrynnau
    Wedi'i Gadw mewn:
  19. 19
    Inhibition of the Hedgehog Pathway in Advanced Basal-Cell Carcinoma

    Inhibition of the Hedgehog Pathway in Advanced Basal-Cell Carcinoma gan Daniel D. Von Hoff, Patricia LoRusso, Charles M. Rudin, Josina C. Reddy, Robert L. Yauch, Raoul Tibes, Glen J. Weiss, Mitesh J. Borad, Christine L. Hann, Julie R. Brahmer, Howard Mackey, B. Lum, Walter C. Darbonne, James C. Marsters, Frédéric J. de Sauvage, Jennifer A. Low

    Cyhoeddwyd 2009
    Cael y testun llawn Cael y testun llawn
    Artigo
    Ychwanegu at ffefrynnau
    Wedi'i Gadw mewn:
  20. 20
    Safety and tolerability of guadecitabine (SGI-110) in patients with myelodysplastic syndrome and acute myeloid leukaemia: a multicentre, randomised, dose-escalation phase 1 study

    Safety and tolerability of guadecitabine (SGI-110) in patients with myelodysplastic syndrome and acute myeloid leukaemia: a multicentre, randomised, dose-escalation phase 1 study gan Jean–Pierre J. Issa, Gail J. Roboz, David A. Rizzieri, Elias Jabbour, Wendy Stock, Casey L. O’Connell, Karen Yee, Raoul Tibes, Elizabeth A. Griffiths, Katherine Walsh, Naval Daver, Woonbok Chung, Sue Naim, Pietro Taverna, Aram Oganesian, Yong Hao, James N. Lowder, Mohammad Azab, Hagop M. Kantarjian

    Cyhoeddwyd 2015
    Cael y testun llawn
    Artigo
    Ychwanegu at ffefrynnau
    Wedi'i Gadw mewn:

Offerynnau Chwilio: